Nucleus plus
  • Patient Care
  • About
 
 

03.21.23

DLL3 CAR T appears promising for SCLC treatment

by ASTCT Science Highlights

Zhang Y, Tacheva-Grigorova SK, Sutton J, et al. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. Clinical Cancer Research. 2023; (doi: 10.1158/1078-0432.CCR-22-2293).

New preclinical evidence suggests that aiming chimeric antigen receptor (CAR) T cells at delta-like ligand 3 (DLL3) may be a viable therapeutic pathway for small cell lung cancer (SCLC). DLL3 is a strong target for immunotherapy in this setting because while it is highly expressed on SCLC and other solid tumors, it is present only at low levels in healthy tissue. To explore, researchers implanted DLL3-expressing tumors in mice, which then received infusions of murine cross-reactive DLL3 CAR T cells. The investigators documented potent anti-tumor activity, including complete responses, in SCLC in vivo models. In vitro, a subset of CARs exhibited long-term killing potential. In addition to the favorable efficacy outcomes, the safety data showed no sign of pituitary or brain toxicity associated with DLL3 CAR T immunotherapy.

Read More

Interim Analysis of KarMMa-3 Trial Finds 51% Reduction in Risk of Progression or Death with Ide-cel in RRMM
05.25.23
Interim Analysis of KarMMa-3 Trial Finds 51% Reduction in Risk of Progression or Death with Ide-cel in RRMM
by Eleanor Mayfield, ELS
IL-18-secreting anti-DLL3 CAR T cells SCLC models
05.23.23
IL-18-secreting anti-DLL3 CAR T cells SCLC models
by ASTCT Science Highlights
TCR-T cells expressing zBBΔBRM shows potent antitumor activity
05.22.23
TCR-T cells expressing zBBΔBRM shows potent antitumor activity
by ASTCT Science Highlights
footer divider

ASTCT

American Society for Transplantation
and Cellular Therapy

330 North Wabash Avenue, Suite 2000
Chicago, IL 60611, USA
Phone: (312) 321-6820
Fax: (312) 673-6733

facebook youtube twitter linkedin
Login
Search